← Back to headlines
Merck's TroFuse-005 Trial for Endometrial Cancer Meets Primary Endpoints
Merck announced that its Phase 3 TroFuse-005 trial, investigating a treatment for endometrial cancer, successfully met its primary endpoints, marking a significant development in oncology.
23 May, 12:01 — 23 May, 12:01
Sources
Showing 1 of 1 sources
